Table 1.
Characteristics of all included studies.
| Author, Year of Publication, Study Design |
Sample Size (SG/CG) | Mean Age (Years) (SG/CG) | Prostatic Procedure | BC Stage (SG/CG) | Tumor Grade (SG/CG) | Unifocal Tumor (SG/CG) | Multifocal Tumor (SG/CG) | Mean Follow-Up (Months) (SG/CG) | Adjuvant Therapy (SG/CG) | LUTS Assessment |
|---|---|---|---|---|---|---|---|---|---|---|
|
Anastasopoulos, 2012 [20]
Non-RCT |
85 (42/43) | 69/69 | Transurethral resection | NA | NA | ΝA | ΝA | 31/27 | ΝA | NA |
|
Dellabella, 2018 [21]
RCT |
85 (42/43) | 64/63 | Transurethral resection | pTa/pTis: 29/26 pT1: 13/17 |
Low: 16/14 High: 26/29 |
21/24 | 21/19 | 37/35 | BCG: 27/26 | IPSS, Qmax, PVR, FACT-BIQ |
| Gargouri, 2016 [22] Non-RCT | 130 (66/64) | 72/64 | Transurethral resection | NA | NA | 38/26 | 28/38 | 41/42 | BCG: 26/40 | NA |
| Greene, 1972 [23] Non-RCT | 200 (100/100) | NA | Transurethral resection | NA | G1: 57/59 G2: 29/23 G3: 14/18 |
81/77 | 19/23 | NA | NA | ΝA |
|
Ham, 2009 [24]
Non-RCT |
213 (106/107) | 68/66 | Transurethral resection | pTa: 21/19 pT1: 85/88 |
Low: 60/59 High: 46/48 |
58/56 | 48/51 | 50/54 | BCG: 49/54 | Qmax, PVR |
| Iannucci, 2005 [25] Non-RCT | 265 (68/197) | NA | Transurethral resection | NA | ΝA | ΝA | ΝA | NA | NA | ΝA |
|
Jaidane, 2010 [26]
Non-RCT |
170 (85/85) | 71/71 | Transurethral resection | pTa: 9/11 pT1: 76/74 |
G1: 32/33 G2: 45/44 G3: 8/8 |
70/65 | 15/20 | 35/33 | BCG: 69/70 | NA |
|
Kizilay, 2020 [27]
Non-RCT |
186 (73/113) | 62/48 | Transurethral resection | pTa: 49/68 pT1: 24/36 pT2: 0/9 |
Low: 51/70 High: 22/43 |
62/89 | 11/24 | NA | ΝA | NA |
|
Li, 2013 [28]
RCT |
62 (25/37) | 48/66 | Photoselective vaporization | pTa: 3/6 pT1: 17/22 pT2: 5/9 |
Low: 20/28 High: 5/9 |
19/25 | 6/12 | NA | BCG: NA, SIIC: all patients |
NA |
|
Laor, 1981 [29]
Non-RCT |
287 (137/150) | 71/60 | Transurethral resection | NA | G1: 51/58 G2: 35/35 G3: 51/57 |
112/124 | 25/26 | 69/96 | NA | ΝA |
|
Li, 2013 [28]
RCT |
62 (25/37) | 48/66 | Photoselective vaporization | pTa: 3/6 pT1: 17/22 pT2: 5/9 |
Low: 20/28 High: 5/9 |
19/25 | 6/12 | NA | BCG: NA, SIIC: all patients |
NA |
|
Park, 2009 [30]
Non-RCT |
189 (24/165) | 70/64 | Transurethral resection | pTa/pTis: 8/56 pT1: 16/109 |
Low: 13/81 High: 11/84 |
NA | NA | 52/44 | BCG: 22/157 | NA |
|
Singh, 2009 [31]
RCT |
48 (24/24) | 56/57 | Transurethral resection | pTa: 17/18 pT1: 7/6 |
G1: 10/9 G2:11/11 G3: 3/4 |
24/24 | 0/0 | 36/38 | NA | IPSS |
|
Ugurlu, 2007 [32]
Non-RCT |
65 (31/34) | 68/56 | Transurethral resection | pTa: 25/25 pT1: 6/9 |
G1: 26/31 G2: 3/3 G3: 2/0 |
31/34 | 0/0 | 31/27 | NA | ΝA |
| Vicente, 1988 [33] Non-RCT | 200 (100/100) | 69/60 | Transurethral resection | pTa: 21/24 pT1: 79/76 |
G1: 4/18 G2: 78/73 G3: 18/9 |
58/52 | 42/48 | 47/46 | None | ΝA |
|
Wang, 2020 [34]
Non-RCT |
236 (118/118) | 67/65 | Thulium laser enucleation | pTa: 14/21 pT1: 114/97 |
Low: 71/79 High: 47/39 |
75/82 | 43/36 | 59/56 | BCG: based on risk, SIIC: 89/93 | Qmax, PVR |
BC: bladder cancer; BCG: bacillus Calmette–Guérin; CG: control group; LUTS: lower urinary tract symptoms; NA: not available; Qmax: maximum flow rate; RCT: randomized controlled trial; SG: simultaneous group; SIIC: single intravesical instillation of chemotherapy; PVR: postvoid residual.